Literature DB >> 18942105

Flow cytometric differential of leukocyte populations in normal bone marrow: influence of peripheral blood contamination.

R A Brooimans1, J Kraan, W van Putten, J J Cornelissen, B Löwenberg, J W Gratama.   

Abstract

BACKGROUND: Availability of immunophenotypic reference values for the various leukocyte populations distributed in bone marrow may be helpful to recognize abnormal bone marrow development and, therefore, useful as first screening of individuals with suspected hematological malignancies or other hematopoietic disorders.
METHODS: A single tube four-color staining panel (CD66abce/CD14/CD45/CD34) together with a predefined gating strategy was utilized to immunologically differentiate the distribution of the major leukocyte populations in bone marrow aspirates of healthy donors. The sample-blood erythrocyte ratio was applied to assess the amount of blood contamination of marrow and account for this in the marrow value estimates.
RESULTS: The frequency of the major leukocyte populations in bone marrow of 134 normal donors were for granulocytes: mean, 69.4%; SD, 10.3%; monocytes: mean, 4.7%; SD, 2.3%; lymphocytes: mean, 18.3%; SD, 8.7%. The frequency of the immature cell population that included precursor cells of each of the cell lineages among other cell types were mean 5.0%; SD 2.2%. The mean percentage of CD34 positive cells was 1.5%; SD 0.7%. Our results showed further that the frequency of cell populations, of which the presence is restricted to the bone marrow (e.g., CD34+ progenitor cells), is influenced by the degree of peripheral blood admixture. Between the total immature cells and purity of the bone marrow, there was a significant positive correlation demonstrated, whereas a negative correlation was found between the percentages of both lymphocytes as monocytes and the purity of the bone marrow.
CONCLUSIONS: With a single tube-staining panel, we obtained reference values for flow cytometric assessment of all relevant leukocyte populations present in bone marrow that can be used as a frame of reference for better recognition of individuals with abnormal hematopoiesis. In addition, we have demonstrated the influence of the degree of peripheral blood admixture in the bone marrow aspirates on those reference values.
Copyright © 2008 Clinical Cytometry Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18942105     DOI: 10.1002/cyto.b.20439

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  15 in total

1.  Transitional B cell subsets in human bone marrow.

Authors:  S Agrawal; S A B C Smith; S G Tangye; W A Sewell
Journal:  Clin Exp Immunol       Date:  2013-10       Impact factor: 4.330

2.  Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.

Authors:  Valérie Bardet; Orianne Wagner-Ballon; Julien Guy; Céline Morvan; Camille Debord; Franck Trimoreau; Emmanuel Benayoun; Nicolas Chapuis; Nicolas Freynet; Cédric Rossi; Stéphanie Mathis; Marie-Pierre Gourin; Andréa Toma; Marie C Béné; Jean Feuillard; Estelle Guérin
Journal:  Haematologica       Date:  2015-01-30       Impact factor: 9.941

Review 3.  Quantification and three-dimensional microanatomical organization of the bone marrow.

Authors:  Cesar Nombela-Arrieta; Markus G Manz
Journal:  Blood Adv       Date:  2017-02-14

4.  Development of mature and functional human myeloid subsets in hematopoietic stem cell-engrafted NOD/SCID/IL2rγKO mice.

Authors:  Satoshi Tanaka; Yoriko Saito; Jun Kunisawa; Yosuke Kurashima; Taichi Wake; Nahoko Suzuki; Leonard D Shultz; Hiroshi Kiyono; Fumihiko Ishikawa
Journal:  J Immunol       Date:  2012-05-18       Impact factor: 5.422

5.  Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood.

Authors:  Anna M Aalbers; Marry M van den Heuvel-Eibrink; Irith Baumann; Michael Dworzak; Henrik Hasle; Franco Locatelli; Barbara De Moerloose; Markus Schmugge; Ester Mejstrikova; Michaela Nováková; Marco Zecca; C Michel Zwaan; Jeroen G Te Marvelde; Anton W Langerak; Jacques J M van Dongen; Rob Pieters; Charlotte M Niemeyer; Vincent H J van der Velden
Journal:  Haematologica       Date:  2014-11-25       Impact factor: 9.941

6.  Bone marrow T-cell percentage: A novel prognostic indicator in acute myeloid leukemia.

Authors:  Manar M Ismail; Nahla A B Abdulateef
Journal:  Int J Hematol       Date:  2016-12-01       Impact factor: 2.490

7.  A Novel Method to Assess Bone Marrow Purity is Useful in Determining Blast Percentage by Flow Cytometry in Acute Myeloid Leukemia and Myelodysplasia.

Authors:  A M Aldawood; Z Kinkade; F G Rosado; O A Esan; L F Gibson; J A Vos
Journal:  Ann Hematol Oncol       Date:  2015

8.  Does the human skeletal muscle harbor the murine equivalents of cardiac precursor cells?

Authors:  Susanne Proksch; Alain Bel; Etienne Puymirat; Laetitia Pidial; Valérie Bellamy; Séverine Peyrard; Jérôme Larghero; Bernard Augereau-Vacher; Philippe Menasché
Journal:  Mol Ther       Date:  2009-02-17       Impact factor: 11.454

Review 9.  Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria.

Authors:  Maria Sanz-De Pedro; Wei Wang; Rashmi Kanagal-Shamanna; Joseph D Khoury
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

Review 10.  Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Authors:  Gerrit J Schuurhuis; Michael Heuser; Sylvie Freeman; Marie-Christine Béné; Francesco Buccisano; Jacqueline Cloos; David Grimwade; Torsten Haferlach; Robert K Hills; Christopher S Hourigan; Jeffrey L Jorgensen; Wolfgang Kern; Francis Lacombe; Luca Maurillo; Claude Preudhomme; Bert A van der Reijden; Christian Thiede; Adriano Venditti; Paresh Vyas; Brent L Wood; Roland B Walter; Konstanze Döhner; Gail J Roboz; Gert J Ossenkoppele
Journal:  Blood       Date:  2018-01-12       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.